Vivitra 440mg Injection

​Vivitra 440mg Injection causes several side effects, which are unwanted symptoms that include:

• Chills and Cough
• Anemia
• Decrease in blood cell counts
• Diarrhea
• Fatigue
• Fever
• Headache
• Heart failure
• Mucosal inflammation
• Infection in the upper respiratory
• Weight loss

If the patients are suffering from the above-mentioned symptoms, do not avoid these symptoms because this injection has severe side effects. Try to contact the doctor immediately for urgent help.

• Vivitra is taken in injection form as per the doctor's prescription.
• The patients should take this injection from a qualified medical professional.
• Do not self-administer.

• ​Vivitra 440mg binds the HER2 protein on the surface of cancer cells.
• The blocking of the HER2 receptor stops signaling, which will stop the growth and division of cancer cells in the patient's body.
• The benefits of the injection are seen in a few weeks or months, depending on the health of the patients after starting treatment.
• However, to see the full benefit, it can take several months or years. As to healthcare professionals.
• Vivitra is a powerful and very effective injection for the treatment of breast cancer.
• However, patients need to discuss benefits and side effects at the beginning of treatment.

It is advisable not to miss any dose. In case you miss a dose of Vivitra 440mg Injection consult your doctor soon. Missing the dose will impact the overall health of the patients. So, it is always advisable to follow the prescription of the doctor strictly.

• Wierzbicki, R., Slamon, D. J., Leyland‑Jones, B., Shak, S., Fuchs, H., Paton, V. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.  New England Journal of Medicine, 344(11), 783–792. https://pubmed.ncbi.nlm.nih.gov/11248153/
  
• Gelber, R. D., Piccart‑Gebhart, M. J., Procter, M., Leyland‑Jones, B., Goldhirsch, A., Untch, M. (2005). Trastuzumab after adjuvant chemotherapy in HER2‑positive breast cancer. New England Journal of Medicine, 353(16), 1659–1672. https://pubmed.ncbi.nlm.nih.gov/16236737/
  
• Tabernero, J., Bang, Y.‑J., Van Cutsem, E., Feyereislova, A., Chung, H.‑C., Shen, L. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2‑positive advanced gastric or gastroesophageal junction cancer: a phase III, open‑label, randomised controlled trial (ToGA). Lancet, 376(9742), 687–697. https://pubmed.ncbi.nlm.nih.gov/20728210/
  
• Zydus Cadila. (2025). Vivitra™ (trastuzumab) prescribing information. Retrieved from the company's information site Macarius Health. (2025). Vivitra 440 mg injection (biosimilar trastuzumab): Product profile. Retrieved from the oncology product database